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Abstract
ABO blood groups are known to influence the plasma level of von Willebrand factor (VWF),
but little is known about the relationship between ABO and coagulation factor VIII (FVIII).
We analyzed the influence of ABO genotypes on VWF antigen, FVIII activity, and their
quantitative relationship in 11,673 participants in the Atherosclerosis Risk in Communities
(ARIC) study. VWF, FVIII, and FVIII/VWF levels varied significantly among O, A (A1 and
A2), B and AB subjects, and the extent of which varied between Americans of European
(EA) and African (AA) descent. We validated a strong influence of ABO blood type on VWF
levels (15.2%), but also detected a direct ABO influence on FVIII activity (0.6%) and FVIII/
VWF ratio (3.8%) after adjustment for VWF. We determined that FVIII activity changed
0.54% for every 1% change in VWF antigen level. This VWF-FVIII relationship differed
between subjects with O and B blood types in EA, AA, and in male, but not female subjects.
Variations in FVIII activity were primarily detected at low VWF levels. These new quantita-
tive influences on VWF, FVIII and the FVIII/VWF ratio help understand how ABO genotypes
differentially influence VWF, FVIII and their ratio, particularly in racial and gender specific
manners.
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Introduction
ABO blood group antigens present on red blood cells are an important determinant of transfu-
sion compatibility. By modifying carbohydrate side chains of soluble and membrane-bound
proteins, they are also involved in physiologic and pathologic processes. ABO blood types have
been associated with the development of coronary heart disease, stroke, and venous thrombo-
embolism [1–3], in part by regulating levels of von Willebrand factor (VWF) and coagulation
factor VIII (FVIII) in the circulation [4;5]. A recent genome wide association study by the
CHARGE consortium shows that single nucleotide polymorphisms (SNPs) with the strongest
association with VWF levels and FVIII activity are in the ABO locus [4].
VWF is synthesized as a pre-pro-polypeptide monomer of 2,813 amino acids [6]. Each
VWF monomer contains 12 potential N- glycosylation and 10 O-glycosylation sites [7], some
that are modified by ABO determinants [8;9]. ABO was originally detected on N-linked glycans
of VWF [8–10], accounting for up to 13% of the N-linked oligosaccharide chains of VWFmul-
timers in the circulation [8;11]. In addition, a recent study also identified 3 O-linked glycans
on VWF that are modified by ABO [12]. The life-span of circulating VWF is known to be influ-
enced by ABO [5;13–16].
Although impacts of ABO on plasma levels and adhesive activity of VWF are well docu-
mented, critically important questions remain. First, is the impact of ABO on levels of VWF
antigen modified by gender and race? Second, is there a direct ABO influence on FVIII activity
that is independent of VWF? A relatively weak VWF-independent impact of ABO on FVIII
has previously been reported [17;18], but the size and racial differences of this effect are
unknown. Without defining this VWF independent effect, it is difficult to answer the question
of whether ABO has a direct or indirect effect on the FVIII/VWF ratio, which is widely used to
evaluate VWF synthesis and its defects in clinical settings [17]. Finally, is the ABO effect modi-
fied by environmental factors known to affect plasma VWF? We have analyzed data from the
Atherosclerosis Risk in Communities (ARIC) study [19–21] to answer these questions. We
have previously used this database to determine that ABO accounts for 15.4% and 10.7% of the
variability of plasma VWF antigen and FVIII activity in a cohort of 10,434 subjects of European
(EA) and African (AA) descents [19;20]. Here, we present data from a cross-sectional study of
11,673 ARIC subjects designed to examine 1) VWF-dependent and independent influences of
ABO on FVIII activity and the FVIII-VWF ratio and 2) gender, racial, and environmental
modifications of these influences.
Materials and Methods
Study population and baseline measurements
ARIC (www.cscc.unc.edu/aric/) is a prospective epidemiologic study conducted in four
US communities, designed to investigate the etiology and natural history of atherosclerosis
and clinical atherosclerotic diseases, as well as variation in cardiovascular risk factors, medical
care, and disease by race, gender, location, and date [22;23]. To examine the intrinsic effects
of ABO on VWF and FVIII, adjustments were made for covariates known to affect VWF anti-
gen and FVIII activity in the circulation; including age, race, gender, body mass index (BMI),
hypertension, diabetes and history of smoking [24;25]. The use of the ARIC data was approved
by the institutional review boards of all participating institutions for the ARIC study.
VWF antigen levels and FVIII activity were measured as previously described [19;20]. The
reliability coefficient (1 –intra-individual variance/total variance) obtained from repeat testing
of individuals over several weeks was 0.68 for VWF and 0.86 for FVIII.
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ABO genotyping
ABO was genotyped using two SNPs: RS8176719 and RS8176746 (S1 Table). Subjects were
classified as type O (OO), type A (AA or AO), type B (BB or BO) or type AB (AB) using these
two SNPs. The A subjects were further genotyped as A1 (including A1O), A1A2, and A2
(including A2O) using haplotypes from the ABO SNPs rs8176749, rs8176704 and rs687289
[26].
Statistical analysis
Distributions of VWF levels and FVIII activity were evaluated to assess normality. Since distri-
butions of the two factors were highly skewed, a natural log transformation was performed
prior to regression analysis. The simple linear and multiple linear regression models and the
least square regression plots were used to investigate relations among VWF levels, FVIII activ-
ity, and the FVIII/VWF ratio. Omega squared (ω2) and semipartial ω2 were calculated to
evaluate effect sizes of the model and individual factors on FVIII activity and FVIII/VWF ratio,
respectively. For assessing difference between groups, analysis of variance (ANOVA) or analy-
sis of covariance (ANCOVA) was performed. Multiple comparisons were corrected by the
Bonferroni method and p< 0.0045 was considered to be statistically significant. All analyses
were performed using SAS 9.2 (SAS Institute, Cary, NC) or R 2.13.2.
Results
Baseline characteristics
A total of 11,673 ARIC subjects were included in this cross-sectional study, comprised of 8,817
EA and 2,856 AA subjects. The features and potential confounding characteristics of this
demographic are summarized in Table 1. The distribution of ABO blood groups was consistent
with previous reports [24]. Among covariates known to affect VWF levels in the circulation,
diabetes and hypertension were more common in subjects with type B blood. The B type sub-
jects also had the highest BMI.
Table 1. Baseline Characteristics of Subjects in Each ABO Blood Group‡.
ABO blood group
Characteristic Total O A1 A1A2 A2 B AB P value
N 11,673
†Age: mean (SD) 54.0 (5.7) 53.9 (5.7) 54.2 (5.7) 54.2 (5.6) 54.0 (5.7) 54.0 (5.8) 53.7 (5.8) 0.41*
AA Female 1,787 901 (50.4%) 320 (17.9%) 17 (1.0%) 150 (8.4%) 328 (18.4%) 71 (4.0%)
AA Male 1,069 558 (52.2%) 157 (14.7%) 11 (1.0%) 67 (6.3%) 230 (21.5%) 46 (3.0%)
EA Female 4,688 1,880 (40.1%) 1,644 (35.1%) 131 (2.8%) 401 (8.6%) 443 (9.4%) 189 (4.0%)
EA Male 4,129 1,666 (40.3%) 1,358 (32.9%) 130 (3.1%) 407 (9.9% 397 (9.6%) 171 (4.1%)
BMI: mean (SD) 27.6 (5.3) 27.8 (5.4) 27.2 (5.0) 27.3 (4.8) 27.5 (4.8) 28.0 (5.6) 27.8 (5.5) <0.0001*
Ever smoking 6,810 (58.4%) 2,874 (57.5%) 2,036 (58.5%) 188 (65.1%) 617 (60.4%) 807 (57.8%) 288 (60.4%) 0.08**
Hypertension 3,907 (33.6%) 1,730 (34.8%) 1,076 (31.1%) 78 (27.1%) 330 (32.4%) 542 (38.9%) 151 (31.9% <0.0001**
Diabetes 1,281 (11.0%) 548 (11.0%) 345 (9.9%) 31 (10.7%) 101 (9.9%) 204 (14.7%) 52 (10.9%) 0.0002**
‡11,673 subjects were included in the study, but for covariates the numbers of subjects were 11,661 for BMI
† Age at baseline visit
* Analysis of variance
** Chi-square test
doi:10.1371/journal.pone.0132626.t001
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Influence of ABO on VWF and FVIII
VWF levels were the highest in subjects with either B or AB blood group, whereas they were
the lowest in O subjects in all four gender-by-race groups (Table 2). The difference in VWF
antigen levels among the six ABO blood groups remained statistically significant after adjust-
ment for environmental covariates (Table 2, second rows). The overall difference in the
mean VWF antigen between type O subjects and those with B blood group was 31.7%. This
difference was significantly greater for AA subjects (32.3% and 32.5% for females and males,
respectively) than for EA subjects (29.8% and 29.1% for females and males, respectively, P<
0.001). Although genotyped as A and B subjects, VWF antigen levels were 123 ± 45% and
135 ± 46% for AO and BO subjects, significantly lower than those with homozygous for A
(144 ± 52%, p<0.0001) and B alleles (160 ± 53%, p = 0.0042), respectively. Furthermore, VWF
Table 2. Geometric Mean (95%CI) of VWF Level (%) in ABO Blood Groups*.
Stratum O A1 A1A2 A2 B AB P value
Overall 92.2 (91.3, 93.1) 124.6 (123.1, 126) 119.8 (115.0,
124.7)
119.8 (115.0,
124.7)
137 (134.5, 139.6) 132.3 (128.2,
136.5)
<0.0001
95.2 (94.2, 96.1) 132.1 (130.5,
133.8)
127.6 (122.7,
132.6)
100.1 (98.1, 102.2) 138.3 (135.9,
140.8)
138.0 (133.9,
142.2)
<0.0001
AA 103.5 (101.6,
105.5)
144.7 (139.9,
149.6)
144.6 (126.0,
166.1)
111.8 (106.4,
117.5)
156.5 (151.7,
161.4)
156.3 (146.1,
167.2)
<0.0001
103.4 (101.5,
105.4)
143.1 (138.5,
148.0)
145.7 (127.3,
166.7)
111.2 (105.8,
116.8)
155.8 (151.1,
160.7)
155.5 (145.4,
166.3)
<0.0001
EA 87.9 (86.9, 88.8) 121.6 (120.2,
123.1)
117.4 (112.8,
122.2)
91.7 (89.6, 93.8) 125.5 (122.7,
128.3)
125.3 (121.1,
129.7)
<0.0001
87.8 (86.9, 88.8) 121.7 (120.3,
123.1)
116.8 (112.3,
121.4)
91.7 (89.7, 93.8) 124.9 (122.2,
127.6)
125.8 (121.7,
130.0)
<0.0001
Female 91.8 (90.6, 93.0) 124.3 (122.4,
126.2)
122.9 (116.1,
130.1)
95.7 (92.9, 98.6) 137.9 (134.5,
141.4)
132.7 (127.1,
138.5)
<0.0001
94.4 (93.3, 95.7) 131.8 (129.7,
133.9)
131.6 (124.8,
138.9)
99.2 (96.5, 102.0) 139.0 (135.8,
142.3)
137.6 (132.2,
143.3)
<0.0001
Male 92.7 (91.3, 94.0) 124.9 (122.7,
127.1)
116.6 (110.1,
123.5)
95.5 (92.6, 98.6) 136.0 (132.3,
139.7)
131.8 (125.9,
138.1)
<0.0001
96.1 (94.7, 97.6) 132.4 (129.9,
135.0)
123.7 (117.0,
130.8)
101.3 (98.2, 104.5) 137.5 (133.9,
141.1)
138.5 (132.4,
144.9)
<0.0001
AA
female
104.7 (102.1,
107.2)
147.1 (141.2,
153.2)
149.7 (125.4,
178.8)
112.5 (106.0,
119.5)
158.5 (152.2,
165.1)
159.2 (146.0,
173.7)
<0.0001
105.0 (102.6,
107.6)
145.5 (139.8,
151.4)
153.1 (128.8,
182.0)
112.8 (106.4,
119.7)
159.3 (153.1,
165.7)
157.1 (144.2,
171.2)
<0.0001
AA male 101.7 (98.6, 104.9) 140.0 (132.1,
148.4)
137.1 (110.0,
170.9)
110.2 (100.8,
120.5)
151.9 (136.3,
169.1)
153.6 (146.4,
161.2)
<0.0001
101.9 (98.8, 105.0) 140.6 (132.7,
149.0)
136.3 (109.7,
169.3)
110.1 (100.8,
120.2)
151.8 (144.7,
159.3)
153.9 (138.2,
171.3)
<0.0001
EA
female
86.2 (84.9, 87.5) 120.3 (118.4,
122.2)
119.8 (113.2,
126.7)
90.1 (87.2, 93.1) 124.4 (120.6,
128.3)
123.9 (118.2,
129.9)
<0.0001
86.3 (85.0, 87.5) 120.4 (118.5,
122.2)
119.1 (112.9,
125.7)
89.7 (87.0, 92.5) 124.1 (120.5,
127.7)
124.4 (118.9,
130.1)
<0.0001
EA male 89.8 (88.4, 91.3) 123.3 (121.1,
125.5)
115.0 (108.6,
121.8)
93.3 (90.3, 96.4) 126.7 (122.6,
131.0)
126.9 (120.7,
133.4)
<0.0001
89.6 (88.2, 91.0) 123.2 (121.1,
125.3)
114.8 (108.6,
121.3)
93.9 (91.0, 96.9) 125.8 (121.9,
129.9)
127.6 (121.5,
133.9)
<0.0001
* For all strata, top rows: unadjusted values and bottom rows: values adjusted for age, smoking, BMI, diabetes, and hypertension (race and gender were
also included for overall population; race in the gender-speciﬁc analyses and gender in the race-speciﬁc analyses)
doi:10.1371/journal.pone.0132626.t002
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levels differed significantly among A1, A1A2, and A2 genotypes overall and for all 8 gender-
by-race groups (p< 0.0001).
Consistent with VWF distribution, FVIII activity was also the lowest in subjects with blood
group O and highest in those with either B or AB before and after adjustment for environmen-
tal factors (Table 3). Overall, type O subjects had a mean FVIII activity that was 76.7% of those
with blood type B, and further analyses indicate a significant racial, but not gender dependent
difference between O and B subjects (p< 0.001). The overall difference between the highest
and lowest FVIII activity (O vs. B or AB) was reduced from 23.3% to 6.2% after adjustment for
VWF (Table 3, second rows). This reduction was similarly observed in all four gender-by-race
groups. FVIII activity was significantly different among subjects with A1, A1A2, and A2 geno-
types, but further gender-by-race group analyses found that the difference was found only in
EA, but not in AA subjects of both genders after the values were adjusted for not only environ-
mental factors, but also for VWF (Table 4).
We have previously shown that ABO contributes to 10.7% of FVIII variability before adjust-
ment for VWF [22], and this study further found that the level of influence was reduced to
0.6% after the VWF adjustment (Table 5, left column). These data are consistent with a strong
VWF influence on the variability of FVIII activity in the plasma (quantified to be 35.5%), but
also demonstrated a small, but significant VWF-independent influence. We have previously
shown that age and BMI contributed to 4.39% and 1.61% of VWF variability [20], but their
influences on variability of FVIII activity and FVIII/VWF ratio were minimal (Table 5). So
were hypertension, diabetes, and ever smoking status. Race and gender together accounted for
1.15% and 0.83% of variability of FVIII and FVIII/VWF ratio.
Association of ABO with FVIII/VWF ratio
The mean FVIII/VWF ratio was examined among the six ABO blood groups (Table 6). Sub-
jects with O blood group had a significantly higher FVIII/VWF ratio followed by those with A,
B, or AB blood group, before and after adjustment for environmental covariates. Similar to
FVIII activity, difference among A1, A1A2, and A2 subjects did not reach statistical signifi-
cance in AA subjects after the Bonferroni correction (data now shown). Quantitatively, ABO
contributed 5% of the variability of the FVIII/VWF ratio (Table 5, right column), whereas envi-
ronmental covariates minimally influenced it.
Interaction between VWF and FVIII
FVIII activity and VWF antigen level correlated well for the entire cohort (S1 Fig) and for four
race-by-gender groups (S2 Fig, A1, A1A2, and A2 subjects were analyzed together), with corre-
lation coefficients ranging from 0.57 to 0.79. To delineate a quantitative relation between VWF
and FVIII and understand how race and gender may modify this relationship, we plotted log
VWF level and log FVIII activity on a coordinated plane. The least-squares trend line suggests
an overall linear relationship between the two measurements (R2 = 0.54, S1 Fig): there was a
0.54% change in FVIII activity for every 1% change in VWF antigen level. This VWF-FVIII
relationship had significantly different slopes between subjects with O and B blood groups for
EA, AA, and male, but not female subjects (Table 7). These different slopes resulted in varia-
tions in FVIII activity among ABO groups primarily detected at low VWF levels.
Discussion
While the influence of ABO on VWF has been extensively studied and widely reported, we
have provided quantitative data on the association of ABO with FVIII activity, its modification
by VWF, and the FVIII/VWF ratio. The large sample size allowed us to conduct racial and
ABO Influence on VWF and Factor VIII
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Table 3. Geometric Mean (95%CI) of FVIII Activity (%) in ABO Blood Groups*.
Stratum O A1 A1A2 A2 B AB P value
112.4 (111.6,
113.3)
136.1 (134.9,
137.2)
130.7 (126.8,
134.8)
115.8 (113.9,
117.6)
146.5 (144.5,
148.6)
142.4 (139.1,
145.8)
<0.0001
Overall 115.2 (114.4,
116.0)
142.7 (141.5,
144.0)
138.1 (134.3,
142.1)
120.3 (118.5,
122.1)
147.0 (145.1,
148.9)
147.4 (144.2,
150.7)
<0.0001
122.5 (121.8,
123.2)
129.8 (128.9,
130.8)
127.7 (125.0,
130.5)
124.9 (123.4,
126.3)
130.8 (129.5,
132.2)
131.3 (129.1,
133.5)
<0.0001
125.1 (123.3,
126.9)
156.2 (152.4,
160.1)
154.7 (139.6,
171.5)
129.8 (125.1,
134.7)
165.1 (161.3,
168.9)
167.6 (159.4,
176.2)
<0.0001
AA 124.8 (123.1,
126.5)
154.2 (150.5,
158.0)
154.6 (140.2,
170.5)
129.1 (124.6,
133.8)
164.1 (160.5,
167.8)
167.0 (159.1,
175.3)
<0.0001
135.4 (134.0,
136.8)
142.3 (139.8,
144.8)
141.4 (131.7,
151.8)
135.1 (131.7,
138.7)
145.2 (142.7,
147.6)
147.9 (142.7,
153.2)
<0.0001
107.6 (106.8,
108.5)
133.1 (131.9,
134.3)
128.4 (124.6,
132.3)
112.3 (110.4,
114.2)
135.4 (133.1,
137.6)
135.1 (131.7,
138.6)
<0.0001
EA 107.4 (106.6,
108.2)
132.9 (131.8,
134.0)
128.0 (124.5,
131.7)
112.2 (110.4,
114.1)
134.6 (132.4,
136.7)
135.3 (132.1,
138.6)
<0.0001
116.4 (115.6,
117.1)
123.6 (122.8,
124.5)
121.5 (118.8,
124.1)
119.2 (117.7,
120.7)
123.7 (122.2,
125.2)
124.0 (121.7,
126.3)
<0.0001
114.6 (113.5,
115.7)
139.3 (137.7,
140.9)
137.0 (131.3,
142.9)
118.7 (116.1,
121.4)
149.4 (146.6,
152.2)
146.4 (141.8,
151.2)
<0.0001
Female 117.0 (115.9,
118.1)
145.7 (144.1,
147.4)
144.7 (139.2,
150.5)
122.1 (119.6,
124.6)
149.8 (147.2,
152.3)
150.8 (146.4,
155.3)
<0.0001
124.7 (123.8,
125.7)
132.9 (131.7,
134.1)
132.1 (128.2,
136.1)
127.2 (125.2,
129.2)
133.2 (131.5,
135.0)
134.8 (131.8,
137.9)
<0.0001
109.8 (108.6,
111.0)
132.0 (130.2,
133.7)
124.5 (119.3,
129.9)
112.4 (109.8,
115.1)
143.1 (140.2,
146.0)
137.8 (133.2,
142.7)
<0.0001
Male 113.5 (112.3,
114.8)
139.7 (137.7,
141.7)
131.8 (126.5,
137.3)
118.6 (115.9,
121.4)
144.3 (141.5,
147.1)
143.9 (139.3,
148.8)
<0.0001
120.3 (119.3,
121.4)
126.7 (125.3,
128.1)
123.5 (119.8,
127.4)
122.5 (120.5,
124.7)
128.5 (126.6,
130.4)
127.7 (124.6,
131.0)
<0.0001
127.6 (125.3,
130.0)
160.8 (156.0,
165.8)
157.7 (138.2,
180.0)
131.4 (125.7,
137.4)
168.2 (163.2,
173.3)
172.0 (161.3,
183.5)
<0.0001
AA
female
128.2 (126.0,
130.4)
159.0 (154.4,
163.7)
159.3 (140.5,
180.5)
132.0 (126.5,
137.8)
169.9 (159.7,
180.8)
169.0 (164.2,
173.9)
<0.0001
138.5 (136.6,
140.4)
146.8 (143.6,
150.1)
143.5 (130.7,
157.6)
137.8 (133.5,
142.2)
149.4 (146.1,
152.8)
151.2 (144.3,
158.4)
<0.0001
121.0 (118.3,
123.8)
147.2 (141.0,
153.6)
150.2 (127.8,
176.6)
126.4 (118.3,
134.9)
160.8 (155.2,
166.6)
161.0 (148.7,
174.2)
<0.0001
AA male 121.3 (118.6,
124.0)
148.4 (142.4,
154.8)
148.8 (127.2,
174.1)
127.0 (119.1,
135.4)
158.7 (153.3,
164.4)
163.6 (151.3,
176.8)
<0.0001
131.8 (129.7,
133.9)
136.1 (132.2,
140.1)
138.7 (124.5,
154.4)
132.5 (126.8,
138.5)
139.8 (136.3,
143.3)
143.0 (135.5,
150.9)
0.0021
108.8 (107.6,
110.0)
135.5 (133.9,
137.1)
134.5 (129.0,
140.2)
114.3 (111.6,
117.1)
136.8 (133.7,
139.9)
137.8 (133.1,
142.7)
<0.0001
EA
female
108.8 (107.7,
110.0)
135.4 (134.0,
137.0)
134.2 (129.0,
139.5)
114.0 (111.4,
116.5)
136.4 (133.5,
139.3)
138.6 (134.1,
143.2)
<0.0001
118.2 (117.2,
119.2)
126.1 (125.0,
127.2)
125.5 (121.8,
129.4)
121.5 (119.4,
123.7)
125.2 (123.1,
127.3)
127.1 (123.9,
130.4)
<0.0001
106.3 (105.0,
107.5)
130.3 (128.6,
132.0)
122.5 (117.4,
127.8)
110.3 (107.7,
112.9)
133.8 (130.6,
137.1)
132.2 (127.4,
137.2)
<0.0001
EA male 106.1 (104.9,
107.3)
130.4 (128.7,
132.0)
122.4 (117.5,
127.5)
110.6 (108.1,
113.2)
132.8 (129.8,
136.0)
132.4 (127.7,
137.2)
<0.0001
(Continued)
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gender subgroup analyses that have not previously been done due to smaller sample sizes. We
also examined the quantitative relationship between VWF level and FVIII activity. Consistent
with previous reports [24;27], we detected a significant influence of ABO on VWF levels,
accounting for 15.2% of overall VWF variability. VWF antigen also differed among A1, A1A2,
and A2 subjects. VWF antigen was the lowest in subjects with O blood groups and highest in
those with either B or AB blood groups. A significant ABO dose effect on VWF level was
detected between AA and AO as well as BB and BO genotypes. In addition to validation of pre-
vious findings in smaller samples, we made several novel observations on quantitative impacts
on how ABO influenced VWF, FVIII and their ratio.
First, the impact of ABO on VWF has been well documented and reaffirmed recently by the
CHARGE Consortium genome-wide association study [4;7;8]. However, whether ABO influ-
ences FVIII through VWF-dependent and/or-independent means remains poorly defined. On
one hand, Smith NL, et al [4] suggested that the transport and chaperoning function of VWF
for FVIII was responsible for the association between ABO and FVIII activity. This notion is
supported by an earlier study of 158 monozygotic and dizygotic twins where the adjustment
Table 3. (Continued)
Stratum O A1 A1A2 A2 B AB P value
114.7 (113.6,
115.7)
121.3 (120.0,
122.5)
117.7 (114.0,
121.4)
116.9 (114.9,
119.1)
122.3 (120.1,
124.6)
121.1 (117.8,
124.5)
<0.0001
* Top rows: unadjusted values; mid-rows (light grey): adjusted for age, smoking, BMI, diabetes, and hypertension; bottom rows (dark grey): adjusted for
model 2 covariates and VWF
doi:10.1371/journal.pone.0132626.t003
Table 4. Geometric Mean (95%CI) of FVIII Activity (%) in A Blood Groups*.
Stratum A1 A1A2 A2 P value
Overall 142.7 (141.5, 144.0) 138.1 (134.3, 142.1) 120.3 (118.5, 122.1) <0.0001
129.8 (128.9, 130.8) 127.7 (125.0, 130.5) 124.9 (123.4, 126.3) <0.0001
AA 154.2 (150.5, 158.0) 154.6 (140.2, 170.5) 129.1 (124.6, 133.8) <0.0001
142.3 (139.8, 144.8) 141.4 (131.7, 151.8) 135.1 (131.7, 138.7) 0.010
EA 132.9 (131.8, 134.0) 128.0 (124.5, 131.7) 112.2 (110.4, 114.1) <0.0001
123.6 (122.8, 124.5) 121.5 (118.8, 124.1) 119.2 (117.7, 120.7) <0.0001
Female 145.7 (144.1, 147.4) 144.7 (139.2, 150.5) 122.1 (119.6, 124.6) <0.0001
132.9 (131.7, 134.1) 132.1 (128.2, 136.1) 127.2 (125.2, 129.2) <0.0001
Male 139.7 (137.7, 141.7) 131.8 (126.5, 137.3) 118.6 (115.9, 121.4) <0.0001
126.7 (125.3, 128.1) 123.5 (119.8, 127.4) 122.5 (120.5, 124.7) 0.001
AA female 159.0 (154.4, 163.7) 159.3 (140.5, 180.5) 132.0 (126.5, 137.8) <0.0001
146.8 (143.6, 150.1) 143.5 (130.7, 157.6) 137.8 (133.5, 142.2) 0.0068
AA male 148.4 (142.4, 154.8) 148.8 (127.2, 174.1) 127.0 (119.1, 135.4) 0.0006
136.1 (132.2, 140.1) 138.7 (124.5, 154.4) 132.5 (126.8, 138.5) 0.72
EA female 135.4 (134.0, 137.0) 134.2 (129.0, 139.5) 114.0 (111.4, 116.5) <0.0001
126.1 (125.0, 127.2) 125.5 (121.8, 129.4) 121.5 (119.4, 123.7) 0.0005
EA male 130.4 (128.7, 132.0) 122.4 (117.5, 127.5) 110.6 (108.1, 113.2) <0.0001
121.3 (120.0, 122.5) 117.7 (114.0, 121.4) 116.9 (114.9, 119.1) 0.0008
* Top row: values adjusted for age, smoking, BMI, diabetes, and hypertension and bottom row (shaded): values adjusted for environmental factors as in
top row, but also for VWF
doi:10.1371/journal.pone.0132626.t004
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for VWF level abolished FVIII differences between ABO blood groups [28]. On the other hand,
a VWF-independent effect of ABO on FVIII was detected by studying subjects from control
and hemophilic families [18;29]. We found that FVIII activity was highest in samples from
blood group AB or B subjects and lowest in subjects with O blood group before and after
adjustment for environmental covariates. This distribution was in parallel with the VWF distri-
bution among the six blood groups, but the influence of ABO on FVIII variability was reduced
from 10.7% to 0.6% after adjustment for VWF. This suggests that ABO influences FVIII activ-
ity primarily, but not exclusively through VWF. The dominant VWF influence was calculated
to contribute 30.8% of the FVIII variability (Table 5). The finding also suggests that the ABO
modified FVIII, but at a significantly lower level.
Second, the FVIII/VWF ratio is widely used as a means to analyze concordance between
FVIII and VWF in the circulation as well as a marker for VWF synthesis [25]. Here, we further
quantified the ABO contribution to the variability of the FVIII/VWF ratio to be 5%, which is
significantly smaller than the influence of ABO on VWF level (15.2%), but much greater than
the impact on FVIII activity (0.6%).
Third, plasma VWF antigen (22%-412%) and FVIII activity (20%-540%) varied signifi-
cantly among ARIC subjects [19;20]. These large variations are likely due to ABO, intrinsic
genetic variability, and environmental factors. Because ABO differentially influences VWF and
FVIII, we examined a quantitative relationship between these two factors in each of the four
ABO blood groups. FVIII activity was linearly associated with VWF in a logarithmic scale,
with every 1% change in VWF resulting in a 0.54% change in FVIII. The slope for this linear
relationship differed significantly between O and B blood groups for EA, AA, and male sub-
jects, but not for female subjects. This difference in slopes appears to result in a greater varia-
tion of FVIII activity among the four blood groups at low VWF levels (Table 7). Although
this population study could not determine whether it is required to maintain a constant molar
ratio of the two molecules in the circulation, this relationship defines an intrinsic interaction
between FVIII and VWF. It is possible that as a known acute phase reactant, environmental
changes contribute more to high VWF levels, whereas ABO is a predominant factor in regulat-
ing VWF expression in subjects with a low baseline level of VWF.
Table 5. Effect Size (%) of Covariates for FVIII activity and FVIII/VWF ratio.
Semipartial ω2 (%)*
Predictor FVIII activitya FVIII/VWF ratiob
ABO 0.83 5.00
VWF 30.82
Age 0.06 1.13
BMI 0.16 0.04
Hypertension 0.08 0.07
Diabetes 0.07 0.04
Ever smoking 0.14 0.37
Race & gender 1.15 0.83
* Semipartial ω2 is the proportion of variability explained by each factor.
a Model was deﬁned as log FVIII = log VWF + ABO + environmental covariates (age, BMI, hypertension,
diabetes, ever smoking status, and combination of race and gender).
b Model was deﬁned as log FVIII/VWF ratio = ABO + environmental covariates (age, BMI, hypertension,
diabetes, ever smoking status, and combination of race and gender).
doi:10.1371/journal.pone.0132626.t005
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In summary, we have determined that the influence of ABO on FVIII activity is primarily
mediated by VWF, but a small VWF-independent effect (0.6%) was also detected. ABO con-
tributed to 5% variability of the FVIII/VWF ratio. VWF and FVIII are linearly correlated in
logarithmic scale, but the relationship between the two factors varied among the four ABO
types. These observations provide quantitative insights into how ABO differentially influences
VWF, FVIII and the FVIII/VWF ratio and how race and gender modify these influences. The
data also suggest that the influence of ABO on FVIII variability may be greater for subjects
who have low baseline levels of VWF.
Table 6. Geometric Mean (95%CI) of FVIII/VWF Ratio in ABOBlood Groups*.
Stratum O A1 A1A2 A2 B AB P value
Overall 1.22 (1.21, 1.23) 1.09 (1.08, 1.10) 1.09 (1.06, 1.12) 1.21 (1.19, 1.23) 1.07 (1.06, 1.08) 1.08 (1.05, 1.10) <0.0001
1.21 (1.20, 1.22) 1.08 (1.07, 1.09) 1.08 (1.05, 1.11) 1.20 (1.18, 1.22) 1.06 (1.05, 1.08) 1.07 (1.04, 1.09) <0.0001
AA 1.21 (1.19, 1.22) 1.08 (1.05, 1.11) 1.07 (0.97, 1.18) 1.16 (1.12, 1.20) 1.06 (1.03, 1.08) 1.07 (1.02, 1.13) <0.0001
1.21 (1.19, 1.22) 1.08 (1.05, 1.10) 1.06 (0.96, 1.17) 1.16 (1.12, 1.20) 1.05 (1.03, 1.08) 1.07 (1.02, 1.13) <0.0001
EA 1.22 (1.21, 1.23) 1.09 (1.08, 1.10) 1.09 (1.06, 1.13) 1.22 (1.20, 1.25) 1.08 (1.06, 1.10) 1.08 (1.05, 1.11) <0.0001
1.22 (1.21, 1.23) 1.09 (1.08, 1.10) 1.10 (1.06, 1.13) 1.22 (1.20, 1.24) 1.08 (1.06, 1.10) 1.08 (1.05, 1.10) <0.0001
Female 1.25 (1.24, 1.26) 1.12 (1.11, 1.13) 1.11 (1.07, 1.16) 1.24 (1.21, 1.27) 1.08 (1.06, 1.10) 1.10 (1.07, 1.14) <0.0001
1.24 (1.23, 1.25) 1.11 (1.09, 1.12) 1.10 (1.06, 1.15) 1.23 (1.20, 1.26) 1.08 (1.06, 1.10) 1.10 (1.06, 1.13) <0.0001
Male 1.18 (1.17, 1.20) 1.06 (1.04, 1.07) 1.07 (1.02, 1.11) 1.18 (1.15, 1.20) 1.05 (1.03, 1.07) 1.05 (1.01, 1.08) <0.0001
1.18 (1.17, 1.19) 1.05 (1.04, 1.07) 1.06 (1.02, 1.11) 1.17 (1.14, 1.20) 1.05 (1.03, 1.07) 1.04 (1.00, 1.07) <0.0001
AA female 1.22 (1.20, 1.24) 1.09 (1.06, 1.13) 1.05 (0.92, 1.20) 1.17 (1.12, 1.22) 1.06 (1.03, 1.09) 1.08 (1.01, 1.15) <0.0001
1.22 (1.20, 1.24) 1.09 (1.06, 1.13) 1.04 (0.91, 1.18) 1.17 (1.12, 1.22) 1.06 (1.03, 1.09) 1.08 (1.01, 1.15) <0.0001
AA male 1.19 (1.17, 1.22) 1.05 (1.01, 1.09) 1.10 (0.94, 1.27) 1.15 (1.08, 1.22) 1.05 (1.01, 1.08) 1.06 (0.99, 1.14) <0.0001
1.19 (1.17, 1.22) 1.06 (1.01, 1.10) 1.09 (0.94, 1.27) 1.15 (1.09, 1.23) 1.05 (1.01, 1.08) 1.06 (0.99, 1.14) <0.0001
EA female 1.26 (1.25, 1.28) 1.13 (1.11, 1.14) 1.12 (1.08, 1.17) 1.27 (1.24, 1.30) 1.10 (1.07, 1.13) 1.11 (1.07, 1.15) <0.0001
1.26 (1.25, 1.28) 1.13 (1.11, 1.14) 1.13 (1.08, 1.17) 1.27 (1.24, 1.30) 1.10 (1.07, 1.12) 1.11 (1.08, 1.15) <0.0001
EA male 1.18 (1.17, 1.20) 1.06 (1.04, 1.07) 1.07 (1.02, 1.11) 1.18 (1.15, 1.21) 1.06 (1.03, 1.08) 1.04 (1.00, 1.08) <0.0001
1.18 (1.17, 1.20) 1.06 (1.04, 1.07) 1.07 (1.02, 1.11) 1.18 (1.15, 1.21) 1.04 (1.00, 1.08) 1.06 (1.03, 1.08) <0.0001
Top row: unadjusted values; bottom row (shaded): values adjusted for age, smoking, BMI, diabetes, and hypertension (race and gender were also
included for overall population; race in the gender-speciﬁc analyses and gender in the race-speciﬁc analyses)
doi:10.1371/journal.pone.0132626.t006
Table 7. Relationship between log FVIII and log VWF in homozygous ABO types*.
Subject Slope Adjusted p value for interaction
O A1 A2 B
Overall 0.484 0.451 0.485 0.448 0.0025
AA 0.515 0.473 0.530 0.458 0.04
EA 0.488 0.447 0.479 0.419 0.001
Female 0.486 0.445 0.481 0.452 0.12
Male 0.509 0.458 0.486 0.442 0.005
* p-values for comparisons between slopes for O and B blood groups.
Models adjusted for age, smoking, BMI, diabetes, and hypertension (race and gender were also included for overall population; race in the gender-speciﬁc
analyses and gender in the race-speciﬁc analyses).
doi:10.1371/journal.pone.0132626.t007
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